The Conversation (0)
Medifocus Inc. (TSXV:MFS,OTCQX:MDFZF) was issued a new patent by the United States Patent and Trademark Office: “Apparatus and Method for Pre-Conditioning/Fixation and Treatment of Disease with Heat Activation/Release with Thermoactivated Drugs and Gene Products” authored by John Mon, COO for Medifocus.
Medifocus Inc. (TSXV:MFS,OTCQX:MDFZF) was issued a new patent by the United States Patent and Trademark Office: “Apparatus and Method for Pre-Conditioning/Fixation and Treatment of Disease with Heat Activation/Release with Thermoactivated Drugs and Gene Products” authored by John Mon, COO for Medifocus.
As quoted in the press release:
The Title of the patent is “Apparatus and Method for Pre-Conditioning/Fixation and Treatment of Disease with Heat Activation/Release with Thermoactivated Drugs and Gene Products.” The author of this patent is John Mon, COO for Medifocus. John Mon stated, “This patent, along with the other recently issued patents, allows Medifocus to partner up with other bio-tech companies in helping to develop and commercialize targeted thermoactivated/released drugs and gene products which, in our opinion, is the future of medicine.”
Click here to read the Medifocus Inc. (TSXV:MFS,OTCQX:MDFZF) press release
